E525-0285 Screening compound: 2-(4-chlorobenzyl)-3-methyl-N~3~-(2-methylcyclohexyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a][1,3]benzimidazole-3-carboxamide

E525-0285 Screening compound: 2-(4-chlorobenzyl)-3-methyl-N~3~-(2-methylcyclohexyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a][1,3]benzimidazole-3-carboxamide
E525-0285 Screening compound: 2-(4-chlorobenzyl)-3-methyl-N~3~-(2-methylcyclohexyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a][1,3]benzimidazole-3-carboxamide alternative view

Chemical Structure Depiction of ChemDiv screening compound E525-0285
2-(4-chlorobenzyl)-3-methyl-N~3~-(2-methylcyclohexyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a][1,3]benzimidazole-3-carboxamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

E525-0285

Molecular Formula

C26H29ClN4O2 (C26 H29 ClN4 O2)

Compound Name

2-(4-chlorobenzyl)-3-methyl-N~3~-(2-methylcyclohexyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a][1,3]benzimidazole-3-carboxamide

IUPAC name

11-[(4-chlorophenyl)methyl]-12-methyl-N-(2-methylcyclohexyl)-10-oxo-1811-triazatricyclo[7.4.0.0^{27}]trideca-2468-tetraene-12-carboxamide

SMILES

CC(CCCC1)C1NC(C(C)(Cn1c2nc3c1cccc3)N(Cc(cc1)ccc1Cl)C2=O)=O

InChI

InChI=1S/C26H29ClN4O2/c1-17-7-3-4-8-20(17)29-25(33)26(2)16-30-22-10-6-5-9-21(22)28-23(30)24(32)31(26)15-18-11-13-19(27)14-12-18/h5-6,9-14,17,20H,3-4,7-8,15-16H2,1-2H3,(H,29,33)

InChI Key

USHPOHFEWWFVEF-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27599829

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

464.99

Hydrogen Bond Acceptors Count

5.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

5.00

Number of Nitrogen and Oxygen Atoms

6

Partition Coefficient, logP

5.665

Distribution Coefficient, logD

5.665

Water Solubility, LogSw

-5.80

Polar Surface Area

50.692

Acid Dissociation Constant (pKa)

15.04

Base Dissociation Constant (pKb)

3.70

Number of Chiral Centers

3.00

Percent sp3 carbon bonding

42.30

E525-0285 in Drug Discovery

Included in Screening Libraries

Antimitotic Tubulin Library (17355 compounds)

Cyclic Ugi PPI Library (9586 compounds)

PPI Inhibitors Tripeptide Mimetics (23972 compounds)

Protein-Protein Interaction Library (218420 compounds)

Developmental Pathway (Hh/Wnt) Set (2238 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Cancer
  • Digestive system
  • Female
  • Hemic and lymphatic
  • Skin
Mechanism of action:
  • PPI modulators
  • PPI modulators
  • PPI modulators
  • PPI modulators
Structure:
  • Cyclic compounds
  • Mimetics
  • Mimetics
Targets:
  • Others

References: we are preparing a list of scientific research reports with E525-0285 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound E525-0285?
Check Price and Availability of E525-0285, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of E525-0285 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for E525-0285
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for E525-0285
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of E525-0285 available by request